Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225335 · ClinicalTrials.gov registry record · NA

Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females

A NA study of Creatine Absorption in Healthy Adults, sponsored by TSI Group.

Completed
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT07225335 is a NA study of Creatine Absorption in Healthy Adults that has completed, run by TSI Group. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225335, a NA study of Creatine Absorption in Healthy Adults, has completed, sponsored by TSI Group.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creatine concentrations, gastrointestinal symptomatology, and fluid distribution measured through bioelectrical impedance spectroscopy.

Interventions

  • DIETARY_SUPPLEMENT Creatine Monohydrate
  • DIETARY_SUPPLEMENT OptiCreatine

Study Locations (1)

North Carolina

  • Applied Physiology Laboratory (Fetzer Hall, Room 025) - Chapel Hill

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2025-11-05
Est. Completion 2025-12-19
Phase NA

Sponsor

TSI Group

1 total trials

What the Registry Record Tells You About NCT07225335

The ClinicalTrials.gov registry entry for NCT07225335 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TSI Group, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Creatine Absorption in Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Creatine Monohydrate is the first listed.

NCT07225335 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT07225335 about?

NCT07225335 is a clinical study titled "Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females". The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects ...

What is the current status of trial NCT07225335?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2025-11-05. Estimated completion is 2025-12-19.

What conditions does trial NCT07225335 study?

This clinical trial studies the following conditions: Creatine Absorption in Healthy Adults.

What interventions are being tested in trial NCT07225335?

The interventions under investigation include: Creatine Monohydrate (DIETARY_SUPPLEMENT), OptiCreatine (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07225335?

This trial is sponsored by TSI Group, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225335 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.